The Pharma Data

FEBRUARY 8, 2021

IBRANCE is indicated for the treatment of adult patients with HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or in men; or with fulvestrant in patients with disease progression following endocrine therapy. 2,3 In the U.S.,

HR 52

HR Clinical Trials Clinical Trials Containment 52

The Pharma Data

APRIL 7, 2021

months with chemotherapy (HR: 0.43; 95% CI: 0.35-0.54; months (HR: 0.51; 95% CI: 0.41-0.62; The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy in the European Union. Medicines targeting these receptors therefore are not typically effective in treating TNBC. months from 1.7

HR 52

HR Genotype FDA Approval Genotoxicity 52

The Pharma Data

APRIL 14, 2021

Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1/PD-L1 Inhibitor –. – New Indication Marks Second FDA Approval for Trodelvy in 2021 –. Canada, Switzerland and Australia, as well as in Singapore through our partner Everest Medicines.

Genotype 52

Genotype Containment FDA Approval Genotoxicity 52